MK
Martin Kolar
Crohn DiseaseCrohn’s diseasebiosimilarColitis, UlcerativeCT-P13Inflammatory bowel diseaseinfliximabUlcerative colitisCrohn's diseaseDilatation
On Valency
published · living versionsW_4rs6dmcq·v1 · currentpublished
The peak-flux of GRB 221009A measured with GRBAlpha
with Jakub Ripa, Hiromitsu Takahashi, Yasushi Fukazawa, Norbert Werner +40
1 version
Preprints & journals
21 papers in the corpus · 2015–2026Balloon dilation versus endoscopic stricturotomy in the treatment of Crohn's anastomotic stricture: experimental randomized study.41840079 · Ryska, Ondrej, Lukas, Martin, Kolar, Martin et al.2026 · 0 citationsSurgical endoscopy. 2026;40(5):4348-4357
Response.40670025 · Lewandowski, Konrad, Lukas, Martin, Kaniewska, Magdalena et al.2025 · 0 citationsGastrointestinal endoscopy. 2025;102(2):309-310
Risk factors for difficult endoscopic bowel dilation of predominantly shorter and noninflammatory strictures among patients with inflammatory bowel disease: findings from inflammatory bowel disease tertiary centers in Poland and Czech Republic.40044092 · Lewandowski, Konrad, Lukas, Martin, Kaniewska, Magdalena et al.2025 · 4 citationsGastrointestinal endoscopy. 2025;102(4):571-580
Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study.37542737 · Resál, Tamás, Bacsur, Péter, Keresztes, Csilla et al.2024 · 15 citationsInflammatory bowel diseases. 2024;30(5):768-779
Subcutaneous Infliximab in Refractory Crohn's Disease Patients: A Possible Biobetter?38028954 · Cerna, Karin, Duricova, Dana, Lukas, Martin et al.2023 · 18 citationsCrohn's & colitis 360. 2023;5(4):otad040
Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD.37383609 · Coufal, Stepan, Kverka, Miloslav, Kreisinger, Jakub et al.2023 · 7 citationsJournal of immunology research. 2023;2023:1535484
Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy.36704107 · Reiss, Zuzana, Rob, Filip, Kolar, Martin et al.2023 · 9 citationsFrontiers in cellular and infection microbiology. 2022;12:1064537
Association between ustekinumab therapy and changes in specific anti-microbial response, serum biomarkers, and microbiota composition in patients with IBD: A pilot study.36584073 · Rob, Filip, Schierova, Dagmar, Stehlikova, Zuzana et al.2023 · 10 citationsPloS one. 2022;17(12):e0277576
A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts.35234552 · Lukas, M, Kolar, M, Reissigova, J et al.2022 · 12 citationsScandinavian journal of gastroenterology. 2022;57(7):814-824
Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy.34831411 · Schierova, Dagmar, Roubalova, Radka, Kolar, Martin et al.2021 · 35 citationsCells. 2021;10(11)
A novel postgraduate endoscopic course using a large animal model of secondary Crohn's disease stricture.33661380 · Lukas, Martin, Kolar, Martin, Ryska, Ondrej et al.2021 · 7 citationsSurgical endoscopy. 2021;35(6):3199-3204
Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.31905382 · Lukas, Martin, Malickova, K, Kolar, M et al.2021 · 54 citationsJournal of Crohn's & colitis. 2020;14(7):915-919
Novel porcine model of Crohn's disease anastomotic stricture suitable for evaluation and training of advanced endoscopic techniques.32535192 · Lukas, Martin, Kolar, Martin, Ryska, Ondrej et al.2021 · 12 citationsGastrointestinal endoscopy. 2021;93(1):250-256
Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases.32013313 · Park, Sang Hyoung, Park, Jae Cheol, Lukas, Milan et al.2026 · 28 citationsIntestinal research. 2020;18(1):34-44
The efficacy of a non-leaching antibacterial central venous catheter - a prospective, randomized, double-blind study.31142873 · Krikava, Ivo, Kolar, Martin, Garajova, Barbora et al.2021 · 5 citationsBiomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 2020;164(2):154-160
Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort.30277084 · Bálint, Anita, Rutka, Mariann, Kolar, Martin et al.2019 · 12 citationsExpert opinion on biological therapy. 2018;18(11):1181-1187
Fecal zonulin is elevated in Crohn's disease and in cigarette smokers.29034305 · Malíčková, Karin, Francová, Irena, Lukáš, Milan et al.2022 · 78 citationsPractical laboratory medicine. 2017;9:39-44
Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.28504555 · Bálint, Anita, Rutka, Mariann, Végh, Zsuzsanna et al.2017 · 28 citationsExpert opinion on drug safety. 2017;16(8):885-890
Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.28147356 · Kolar, M, Duricova, D, Bortlik, M et al.2017 · 48 citationsDigestive diseases (Basel, Switzerland). 2017;35(1-2):91-100
Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.27106537 · Farkas, Klaudia, Rutka, Mariann, Golovics, Petra A et al.2017 · 83 citationsJournal of Crohn's & colitis. 2016;10(11):1273-1278
Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.26329773 · Bortlik, Martin, Duricova, Dana, Machkova, Nadezda et al.2016 · 54 citationsScandinavian journal of gastroenterology. 2016;51(2):196-202
Career total: 69 works. 21 are in this corpus.
Profile built from the corpus for this byline.
Author records are still filling in while the Hub is in alpha. If this is your page, you'll be able to claim it soon. Spot a mistake? Tell us.